Serum levels of CXCL1, IL-17A, and nitric oxide were lower in the CAPE-treated ETBF/AOM/DSS group compared to the ETBF/AOM/DSS group (Figure 4A–C). The gene discussed is CXCL1; the disease is infectious otitis media.